Effect of chemotherapy on the outcome of self-expandable metallic stents in gastric cancer patients with malignant outlet obstruction

被引:32
作者
Kim, C. G. [1 ]
Park, S. R. [1 ]
Choi, I. J. [1 ]
Lee, J. Y. [1 ]
Cho, S. J. [1 ]
Park, Y. I. [1 ]
Nam, B. H. [2 ]
Kim, Y. W. [1 ]
机构
[1] Natl Canc Ctr, Ctr Gastr Canc, Goyang 410769, Gyeonggi Do, South Korea
[2] Natl Canc Ctr, Ctr Clin Trials, Goyang 410769, Gyeonggi Do, South Korea
关键词
ENDOSCOPIC PALLIATION; MULTICENTER; TRIAL;
D O I
10.1055/s-0032-1309893
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and study aim: Chemotherapy has been suggested to affect the outcome of pyloric stent placement. This study aimed to investigate the association between the response to chemotherapy and pyloric stent outcome. Patients and methods: Data from 113 patients with inoperable gastric cancer who received chemotherapy after pyloric stent placement at the National Cancer Center hospital were analyzed retrospectively. Chemotherapy response was assessed using the Response Evaluation Criteria in Solid Tumors. A Cox proportional hazards model was used to evaluate the effect of chemotherapy response on the complications of stents. Results: The stent migration rate was 15.9% (18/113) and the re-stenosis rate was 30.1% (34/113). The response rates to chemotherapy were higher in the first-line group than in the salvage chemotherapy group (second-line or more) (44.8% [26/58] vs. 3.6% [2/55], respectively; P < 0.001). The proportion of patients with long time-to-progression (>8 weeks) was also higher in the first-line than the salvage chemotherapy group (81.0% [47/58] vs. 61.8% [34/55], respectively; P = 0.036). Although, the response to chemotherapy was not associated with stent migration or re-stenosis, a long time-to-progression (adjusted hazard ratio [aHR] = 0.29, 95% confidence interval [CI] 0.13-0.67) and first-line chemotherapy (aHR = 0.45, 95% CI 0.22-0.93) were protective factors against re-stenosis in the multivariate analysis. In patients who received first-line chemotherapy, the median duration of patency of covered and uncovered stents was 20 weeks (95%CI 11-29) and 33 weeks (95%CI 18-48), respectively (P = 0.317). Conclusions: A long time-to-progression and first-line chemotherapy were significant protective factors against re-stenosis. In chemotherapy-naive gastric cancer patients with pyloric obstruction, placement of an uncovered stent followed by chemotherapy can be considered to increase stent patency.
引用
收藏
页码:807 / 812
页数:6
相关论文
共 20 条
  • [1] Adler DG, 2002, AM J GASTROENTEROL, V97, P72
  • [2] Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
    Ajani, Jaffer A.
    Rodriguez, Wuilbert
    Bodoky, Gyorgy
    Moiseyenko, Vladimir
    Lichinitser, Mikhail
    Gorbunova, Vera
    Vynnychenko, Ihor
    Garin, August
    Lang, Istvan
    Falcon, Silvia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1547 - 1553
  • [3] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Bang, Yung-Jue
    Van Cutsem, Eric
    Feyereislova, Andrea
    Chung, Hyun C.
    Shen, Lin
    Sawaki, Akira
    Lordick, Florian
    Ohtsu, Atsushi
    Omuro, Yasushi
    Satoh, Taroh
    Aprile, Giuseppe
    Kulikov, Evgeny
    Hill, Julie
    Lehle, Michaela
    Ruschoff, Josef
    Kang, Yoon-Koo
    [J]. LANCET, 2010, 376 (9742) : 687 - 697
  • [4] Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer
    Bayraktar, Soley
    Bayraktar, Ulas Darda
    Rocha-Lima, Caio Max
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (06) : 673 - 682
  • [5] Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
    Boku, Narikazu
    Yamamoto, Seiichiro
    Fukuda, Haruhiko
    Shirao, Kuniaki
    Doi, Toshihiko
    Sawaki, Akira
    Koizumi, Wasaburo
    Saito, Hiroshi
    Yamaguchi, Kensei
    Takiuchi, Hiroya
    Nasu, Junichiro
    Ohtsu, Atsushi
    [J]. LANCET ONCOLOGY, 2009, 10 (11) : 1063 - 1069
  • [6] Clinical Outcomes of Self-Expandable Metal Stent and Prognostic Factors for Stent Patency in Gastric Outlet Obstruction Caused by Gastric Cancer
    Cho, Yu Kyung
    Kim, Sang Woo
    Hur, Won Haeng
    Nam, Kwan Woo
    Chang, Jae Hyuck
    Park, Jae Myung
    Lee, In Seok
    Choi, Myung-Gyu
    Chung, In-Sik
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (03) : 668 - 674
  • [7] Capecitabine and oxaliplatin for advanced esophagogastric cancer
    Cunningham, David
    Starling, Naureen
    Rao, Sheela
    Iveson, Timothy
    Nicolson, Marianne
    Coxon, Fareeda
    Middleton, Gary
    Daniel, Francis
    Oates, Jacqueline
    Norman, Andrew Richard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) : 36 - 46
  • [8] Self-expanding metal stents for gastroduodenal malignancies: Systematic review of their clinical effectiveness
    Dormann, A
    Meisner, S
    Verin, N
    Lang, AW
    [J]. ENDOSCOPY, 2004, 36 (06) : 543 - 550
  • [9] Covered versus uncovered self-expandable metallic stents for palliation of malignant pyloric obstruction in gastric cancer patients: a randomized, prospective study
    Kim, Chan Gyoo
    Choi, Il Ju
    Lee, Jong Yeul
    Cho, Soo-Jeong
    Park, Sook Ryun
    Lee, Jun Ho
    Ryu, Keun Won
    Kim, Young-Woo
    Park, Young Iee
    [J]. GASTROINTESTINAL ENDOSCOPY, 2010, 72 (01) : 25 - 32
  • [10] Metallic stent placement in the palliative treatment of malignant gastroduodenal obstructions: prospective evaluation of results and factors influencing outcome in 213 patients
    Kim, Jin Hyoung
    Song, Ho-Young
    Shin, Ji Hoon
    Choi, Eugene
    Kim, Tae Won
    Jung, Hwoon-Yong
    Lee, Gin Hyug
    Lee, Sung Koo
    Kim, Myung-Hwan
    Ryu, Min-Hee
    Kang, Yoon-Koo
    Kim, Byung Sik
    Yook, Jeong Hwan
    [J]. GASTROINTESTINAL ENDOSCOPY, 2007, 66 (02) : 256 - 264